Holdings (Monthly)
Guide ↗
iShares Biotechnology ETF
· iShares Trust| # | Name | Ticker | Since | Shares | Shares Δ | Value | Val Δ% | % Port | Cat |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds III | 066922519 | Mar 2026 | 784,655,767 | +1,928,164 | $784.8M | +0.2% | 9.66% | STIV |
| 2 | Gilead Sciences, Inc. | 375558103 | Mar 2026 | 4,515,707 | +492,782 | $629.4M | +40.9% | 7.75% | EC |
| 3 | Amgen, Inc. | 031162100 | Mar 2026 | 1,733,148 | +153,460 | $609.8M | +36.8% | 7.51% | EC |
| 4 | Vertex Pharmaceuticals, Inc. | 92532F100 | Mar 2026 | 1,354,033 | +191,398 | $604.6M | +32.8% | 7.44% | EC |
| 5 | Regeneron Pharmaceuticals, Inc. | 75886F107 | Mar 2026 | 758,232 | +156,065 | $585.8M | +73.0% | 7.21% | EC |
| 6 | Alnylam Pharmaceuticals, Inc. | 02043Q107 | Mar 2026 | 979,642 | +239,530 | $324.1M | -4.0% | 3.99% | EC |
| 7 | Insmed, Inc. | 457669307 | Mar 2026 | 1,587,887 | +369,063 | $259.7M | +47.9% | 3.20% | EC |
| 8 | Argenx SE | 04016X101 | Mar 2026 | 341,883 | +88,168 | $249.7M | +33.4% | 3.07% | EC |
| 9 | Biogen, Inc. | 09062X103 | Mar 2026 | 1,091,046 | +228,193 | $200.0M | +65.5% | 2.46% | EC |
| 10 | Natera, Inc. | 632307104 | Mar 2026 | 980,622 | +200,465 | $196.1M | +56.2% | 2.41% | EC |
| 11 | United Therapeutics Corp. | 91307C102 | Mar 2026 | 315,509 | +57,570 | $187.1M | +73.0% | 2.30% | EC |
| 12 | BeOne Medicines Ltd. | 07725L102 | Mar 2026 | 529,143 | +161,733 | $157.1M | +25.5% | 1.93% | EC |
| 13 | Incyte Corp. | 45337C102 | Mar 2026 | 1,467,923 | +330,295 | $138.2M | +43.2% | 1.70% | EC |
| 14 | Moderna, Inc. | 60770K107 | Mar 2026 | 2,692,459 | +666,773 | $136.8M | +161.4% | 1.68% | EC |
| 15 | Illumina, Inc. | 452327109 | Mar 2026 | 1,107,291 | +226,312 | $136.5M | +63.1% | 1.68% | EC |
| 16 | Revolution Medicines, Inc. | 76155X100 | Mar 2026 | 1,283,912 | +328,618 | $124.9M | +179.9% | 1.54% | EC |
| 17 | Roivant Sciences Ltd. | N/A | Mar 2026 | 3,642,557 | +2,694,909 | $100.9M | +254.9% | 1.24% | EC |
| 18 | Neurocrine Biosciences, Inc. | 64125C109 | Mar 2026 | 727,502 | +158,564 | $95.8M | +20.0% | 1.18% | EC |
| 19 | Genmab A/S | 372303206 | Mar 2026 | 3,555,098 | +884,567 | $95.4M | +16.5% | 1.17% | EC |
| 20 | Bridgebio Pharma, Inc. | 10806X102 | Mar 2026 | 1,238,687 | +282,546 | $92.0M | +85.2% | 1.13% | EC |
| 21 | Ionis Pharmaceuticals, Inc. | 462222100 | Mar 2026 | 1,205,549 | +273,434 | $90.5M | +48.5% | 1.11% | EC |
| 22 | Medpace Holdings, Inc. | 58506Q109 | Mar 2026 | 169,922 | +36,145 | $81.6M | +18.6% | 1.00% | EC |
| 23 | Madrigal Pharmaceuticals, Inc. | 558868105 | Mar 2026 | 155,341 | +36,454 | $81.3M | +49.1% | 1.00% | EC |
| 24 | Exelixis, Inc. | 30161Q104 | Mar 2026 | 1,871,326 | +334,547 | $80.3M | +26.5% | 0.99% | EC |
| 25 | BioMarin Pharmaceutical, Inc. | 09061G101 | Mar 2026 | 1,412,330 | +297,157 | $79.8M | +32.1% | 0.98% | EC |
| 26 | Ascendis Pharma A/S | 04351P101 | Mar 2026 | 339,948 | +87,969 | $77.8M | +55.2% | 0.96% | EC |
| 27 | Praxis Precision Medicines, Inc. | 74006W207 | Mar 2026 | 195,097 | +78,539 | $62.9M | +917.5% | 0.77% | EC |
| 28 | Charles River Laboratories International, Inc. | 159864107 | Mar 2026 | 362,165 | +75,233 | $62.5M | +39.2% | 0.77% | EC |
| 29 | Arrowhead Pharmaceuticals, Inc. | 04280A100 | Mar 2026 | 975,175 | +218,405 | $61.1M | +134.3% | 0.75% | EC |
| 30 | Vaxcyte, Inc. | 92243G108 | Mar 2026 | 1,045,695 | +305,975 | $60.8M | +128.1% | 0.75% | EC |
| 31 | Bio-Techne Corp. | 09073M104 | Mar 2026 | 1,151,950 | +245,468 | $60.2M | +19.4% | 0.74% | EC |
| 32 | Cytokinetics, Inc. | 23282W605 | Mar 2026 | 896,972 | +207,023 | $59.1M | +55.9% | 0.73% | EC |
| 33 | Halozyme Therapeutics, Inc. | 40637H109 | Mar 2026 | 868,502 | +186,537 | $56.1M | +12.2% | 0.69% | EC |
| 34 | Axsome Therapeutics, Inc. | 05464T104 | Mar 2026 | 319,088 | +76,401 | $53.9M | +83.0% | 0.66% | EC |
| 35 | BioNTech SE | 09075V102 | Mar 2026 | 599,506 | +227,603 | $53.3M | +45.3% | 0.66% | EC |
| 36 | Krystal Biotech, Inc. | 501147102 | Mar 2026 | 188,966 | +42,377 | $48.8M | +88.6% | 0.60% | EC |
| 37 | Protagonist Therapeutics, Inc. | 74366E102 | Mar 2026 | 447,047 | +100,457 | $47.1M | +104.7% | 0.58% | EC |
| 38 | Repligen Corp. | 759916109 | Mar 2026 | 396,896 | +83,327 | $46.8M | +11.6% | 0.58% | EC |
| 39 | Kymera Therapeutics, Inc. | 501575104 | Mar 2026 | 521,385 | +174,201 | $43.4M | +121.0% | 0.53% | EC |
| 40 | Rhythm Pharmaceuticals, Inc. | 76243J105 | Mar 2026 | 474,539 | +111,815 | $41.3M | +12.7% | 0.51% | EC |
| 41 | PTC Therapeutics, Inc. | 69366J200 | Mar 2026 | 593,152 | +144,867 | $40.4M | +46.9% | 0.50% | EC |
| 42 | Cogent Biosciences, Inc. | 19240Q201 | Mar 2026 | 1,009,396 | +345,734 | $38.9M | +307.7% | 0.48% | EC |
| 43 | Arcellx, Inc. | 03940C100 | Mar 2026 | 335,814 | +91,943 | $38.6M | +92.6% | 0.47% | EC |
| 44 | Terns Pharmaceuticals, Inc. | 880881107 | Mar 2026 | 713,848 | +305,389 | $37.6M | +1126.9% | 0.46% | EC |
| 45 | Nuvalent, Inc. | 670703107 | Mar 2026 | 355,481 | +92,138 | $36.4M | +59.9% | 0.45% | EC |
| 46 | Mirum Pharmaceuticals, Inc. | 604749101 | Mar 2026 | 392,677 | +153,038 | $36.3M | +106.5% | 0.45% | EC |
| 47 | Tempus AI, Inc. | 88023B103 | Mar 2026 | 773,906 | +206,714 | $35.0M | -23.6% | 0.43% | EC |
| 48 | Xenon Pharmaceuticals, Inc. | 98420N105 | Mar 2026 | 598,390 | +162,016 | $34.8M | +98.6% | 0.43% | EC |
| 49 | Amicus Therapeutics, Inc. | 03152W109 | Mar 2026 | 2,307,725 | +534,693 | $33.4M | +138.8% | 0.41% | EC |
| 50 | Apellis Pharmaceuticals, Inc. | 03753U106 | Mar 2026 | 778,245 | +163,376 | $31.3M | +125.0% | 0.39% | EC |
| 51 | Apogee Therapeutics, Inc. | 03770N101 | Mar 2026 | 353,520 | +136,480 | $29.8M | +245.1% | 0.37% | EC |
| 52 | Scholar Rock Holding Corp. | 80706P103 | Mar 2026 | 593,730 | +156,810 | $29.2M | +79.4% | 0.36% | EC |
| 53 | ACADIA Pharmaceuticals, Inc. | 004225108 | Mar 2026 | 1,251,241 | +264,275 | $27.9M | +32.2% | 0.34% | EC |
| 54 | Bruker Corp. | 116794108 | Mar 2026 | 764,342 | +157,409 | $27.6M | +40.0% | 0.34% | EC |
| 55 | Crinetics Pharmaceuticals, Inc. | 22663K107 | Mar 2026 | 726,428 | +212,856 | $26.4M | +23.3% | 0.32% | EC |
| 56 | CG oncology, Inc. | 156944100 | Mar 2026 | 379,295 | +102,737 | $25.7M | +130.4% | 0.32% | EC |
| 57 | Spyre Therapeutics, Inc. | 00773J202 | Mar 2026 | 478,909 | +177,524 | $24.2M | +378.2% | 0.30% | EC |
| 58 | Erasca, Inc. | 29479A108 | Mar 2026 | 1,384,399 | +435,673 | $22.4M | +983.0% | 0.28% | EC |
| 59 | Tarsus Pharmaceuticals, Inc. | 87650L103 | Mar 2026 | 297,522 | +70,121 | $20.9M | +54.4% | 0.26% | EC |
| 60 | Twist Bioscience Corp. | 90184D100 | Mar 2026 | 436,795 | +97,212 | $20.8M | +117.2% | 0.26% | EC |
| 61 | Centessa Pharmaceuticals plc | 152309100 | Mar 2026 | 520,762 | +165,959 | $20.7M | +140.4% | 0.25% | EC |
| 62 | Ideaya Biosciences, Inc. | 45166A102 | Mar 2026 | 615,636 | +140,159 | $20.5M | +58.6% | 0.25% | EC |
| 63 | Denali Therapeutics, Inc. | 24823R105 | Mar 2026 | 1,055,210 | +309,336 | $20.3M | +87.1% | 0.25% | EC |
| 64 | Travere Therapeutics, Inc. | 89422G107 | Mar 2026 | 674,600 | +162,993 | $20.0M | +63.9% | 0.25% | EC |
| 65 | ImmunityBio, Inc. | 45256X103 | Mar 2026 | 2,572,701 | +2,011,290 | $19.7M | +1328.8% | 0.24% | EC |
| 66 | Arcutis Biotherapeutics, Inc. | 03969K108 | Mar 2026 | 814,779 | +198,591 | $19.2M | +65.3% | 0.24% | EC |
| 67 | Veracyte, Inc. | 92337F107 | Mar 2026 | 579,343 | +126,112 | $18.7M | +19.9% | 0.23% | EC |
| 68 | Structure Therapeutics, Inc. | 86366E106 | Mar 2026 | 381,676 | +146,308 | $18.4M | +179.1% | 0.23% | EC |
| 69 | Edgewise Therapeutics, Inc. | 28036F105 | Mar 2026 | 572,192 | +132,604 | $18.0M | +152.8% | 0.22% | EC |
| 70 | 10X Genomics, Inc. | 88025U109 | Mar 2026 | 841,716 | +190,578 | $17.9M | +134.8% | 0.22% | EC |
| 71 | Legend Biotech Corp. | 52490G102 | Mar 2026 | 983,928 | +231,507 | $17.8M | -27.5% | 0.22% | EC |
| 72 | Vera Therapeutics, Inc. | 92337R101 | Mar 2026 | 419,778 | +133,613 | $16.9M | +103.1% | 0.21% | EC |
| 73 | Dyne Therapeutics, Inc. | 26818M108 | Mar 2026 | 917,470 | +271,040 | $16.6M | +103.4% | 0.20% | EC |
| 74 | Beam Therapeutics, Inc. | 07373V105 | Mar 2026 | 692,124 | +154,035 | $16.5M | +26.3% | 0.20% | EC |
| 75 | BioCryst Pharmaceuticals, Inc. | 09058V103 | Mar 2026 | 1,715,826 | +520,640 | $16.3M | +80.1% | 0.20% | EC |
| 76 | Sarepta Therapeutics, Inc. | 803607100 | Mar 2026 | 739,607 | +191,742 | $16.1M | +52.4% | 0.20% | EC |
| 77 | Immunovant, Inc. | 45258J102 | Mar 2026 | 626,211 | +209,952 | $15.6M | +131.8% | 0.19% | EC |
| 78 | ADMA Biologics, Inc. | 000899104 | Mar 2026 | 1,711,239 | +352,475 | $15.4M | -22.6% | 0.19% | EC |
| 79 | Adaptive Biotechnologies Corp. | 00650F109 | Mar 2026 | 1,105,997 | +249,550 | $15.4M | +19.8% | 0.19% | EC |
| 80 | Summit Therapeutics, Inc. | 86627T108 | Mar 2026 | 799,477 | +138,225 | $15.2M | +11.0% | 0.19% | EC |
| 81 | Oruka Therapeutics, Inc. | 687604108 | Mar 2026 | 304,331 | +123,392 | $14.9M | +329.0% | 0.18% | EC |
| 82 | Syndax Pharmaceuticals, Inc. | 87164F105 | Mar 2026 | 631,524 | +140,056 | $14.8M | +95.1% | 0.18% | EC |
| 83 | Tango Therapeutics, Inc. | 87583X109 | Mar 2026 | 687,885 | +303,039 | $14.4M | +345.2% | 0.18% | EC |
| 84 | Ultragenyx Pharmaceutical, Inc. | 90400D108 | Mar 2026 | 680,286 | +151,750 | $14.3M | -10.4% | 0.18% | EC |
| 85 | Disc Medicine, Inc. | 254604101 | Mar 2026 | 214,889 | +79,464 | $13.7M | +53.5% | 0.17% | EC |
| 86 | Agios Pharmaceuticals, Inc. | 00847X104 | Mar 2026 | 400,087 | +79,413 | $13.5M | +5.2% | 0.17% | EC |
| 87 | GRAIL, Inc. | 384747101 | Mar 2026 | 261,045 | +84,904 | $13.5M | +29.5% | 0.17% | EC |
| 88 | Zymeworks, Inc. | 98985Y108 | Mar 2026 | 529,981 | +99,818 | $13.3M | +80.6% | 0.16% | EC |
| 89 | Arcus Biosciences, Inc. | 03969F109 | Mar 2026 | 612,355 | +226,556 | $13.2M | +152.1% | 0.16% | EC |
| 90 | BlackRock Funds III | 066922477 | Mar 2026 | 12,996,156 | +1,865,974 | $13.0M | +16.8% | 0.16% | STIV |
| 91 | Aurinia Pharmaceuticals, Inc. | 05156V102 | Mar 2026 | 874,336 | +173,978 | $13.0M | +67.4% | 0.16% | EC |
| 92 | Enliven Therapeutics, Inc. | 29337E102 | Mar 2026 | 322,556 | +97,642 | $12.6M | +174.6% | 0.16% | EC |
| 93 | Day One Biopharmaceuticals, Inc. | 23954D109 | Mar 2026 | 578,773 | +138,686 | $12.4M | +299.9% | 0.15% | EC |
| 94 | Vericel Corp. | 92346J108 | Mar 2026 | 373,502 | +79,186 | $12.0M | +29.7% | 0.15% | EC |
| 95 | Mineralys Therapeutics, Inc. | 603170101 | Mar 2026 | 439,648 | +188,451 | $11.9M | +25.0% | 0.15% | EC |
| 96 | Alumis, Inc. | 022307102 | Mar 2026 | 530,358 | +136,492 | $11.7M | +643.5% | 0.14% | EC |
| 97 | Zai Lab Ltd. | 98887Q104 | Mar 2026 | 613,747 | +158,245 | $11.5M | -25.2% | 0.14% | EC |
| 98 | Nurix Therapeutics, Inc. | 67080M103 | Mar 2026 | 720,848 | +279,011 | $11.2M | +173.7% | 0.14% | EC |
| 99 | Stoke Therapeutics, Inc. | 86150R107 | Mar 2026 | 331,288 | +60,509 | $10.8M | +69.5% | 0.13% | EC |
| 100 | Intellia Therapeutics, Inc. | 45826J105 | Mar 2026 | 835,337 | +239,413 | $10.7M | +4.1% | 0.13% | EC |
| 101 | AnaptysBio, Inc. | 032724106 | Mar 2026 | 192,136 | +41,248 | $10.7M | +130.6% | 0.13% | EC |
| 102 | Recursion Pharmaceuticals, Inc. | 75629V104 | Mar 2026 | 3,419,857 | +1,456,251 | $10.5M | +9.6% | 0.13% | EC |
| 103 | Tyra Biosciences, Inc. | 90240B106 | Mar 2026 | 272,474 | +75,596 | $10.4M | +278.9% | 0.13% | EC |
| 104 | Relay Therapeutics, Inc. | 75943R102 | Mar 2026 | 980,266 | +212,887 | $9.8M | +143.5% | 0.12% | EC |
| 105 | Amylyx Pharmaceuticals, Inc. | 03237H101 | Mar 2026 | 687,536 | +295,304 | $9.6M | +79.3% | 0.12% | EC |
| 106 | Novavax, Inc. | 670002401 | Mar 2026 | 1,157,114 | +284,679 | $9.4M | +24.5% | 0.12% | EC |
| 107 | Iovance Biotherapeutics, Inc. | 462260100 | Mar 2026 | 2,619,021 | +892,738 | $9.2M | +145.4% | 0.11% | EC |
| 108 | Immunocore Holdings plc | 45258D105 | Mar 2026 | 277,185 | +69,042 | $8.4M | +10.5% | 0.10% | EC |
| 109 | Galapagos NV | 36315X101 | Mar 2026 | 271,893 | +67,142 | $8.2M | +15.0% | 0.10% | EC |
| 110 | Grifols SA | 398438408 | Mar 2026 | 976,161 | +260,751 | $7.8M | +9.9% | 0.10% | EC |
| 111 | Nuvation Bio, Inc. | 67080N101 | Mar 2026 | 1,795,888 | +438,463 | $7.7M | +53.4% | 0.09% | EC |
| 112 | Taysha Gene Therapies, Inc. | 877619106 | Mar 2026 | 1,672,180 | +365,284 | $7.5M | +74.9% | 0.09% | EC |
| 113 | Trevi Therapeutics, Inc. | 89532M101 | Mar 2026 | 608,481 | +132,280 | $7.3M | +66.6% | 0.09% | EC |
| 114 | Mesoblast Ltd. | 590717401 | Mar 2026 | 460,143 | +75,080 | $7.1M | +14.1% | 0.09% | EC |
| 115 | Corvus Pharmaceuticals, Inc. | 221015100 | Mar 2026 | 473,326 | +147,124 | $6.9M | +188.0% | 0.09% | EC |
| 116 | Olema Pharmaceuticals, Inc. | 68062P106 | Mar 2026 | 457,751 | +146,215 | $6.8M | +123.8% | 0.08% | EC |
| 117 | Rapport Therapeutics, Inc. | 75383L102 | Mar 2026 | 217,759 | +114,792 | $6.8M | +122.8% | 0.08% | EC |
| 118 | Geron Corp. | 374163103 | Mar 2026 | 4,513,103 | +949,653 | $6.7M | +37.7% | 0.08% | EC |
| 119 | Fortrea Holdings, Inc. | 34965K107 | Mar 2026 | 693,057 | +160,366 | $6.5M | +45.6% | 0.08% | EC |
| 120 | Vir Biotechnology, Inc. | 92764N102 | Mar 2026 | 704,449 | +176,192 | $6.3M | +109.3% | 0.08% | EC |
| 121 | Xencor, Inc. | 98401F105 | Mar 2026 | 513,267 | +118,251 | $6.2M | +33.6% | 0.08% | EC |
| 122 | AbCellera Biologics, Inc. | 00288U106 | Mar 2026 | 1,732,022 | +402,852 | $6.0M | -9.6% | 0.07% | EC |
| 123 | CareDx, Inc. | 14167L103 | Mar 2026 | 337,886 | +45,219 | $5.9M | +37.8% | 0.07% | EC |
| 124 | Monte Rosa Therapeutics, Inc. | 61225M102 | Mar 2026 | 346,430 | +74,368 | $5.7M | +182.7% | 0.07% | EC |
| 125 | KalVista Pharmaceuticals, Inc. | 483497103 | Mar 2026 | 276,916 | +56,092 | $5.6M | +107.3% | 0.07% | EC |
| 126 | Janux Therapeutics, Inc. | 47103J105 | Mar 2026 | 392,349 | +73,384 | $5.5M | -30.0% | 0.07% | EC |
| 127 | MannKind Corp. | 56400P706 | Mar 2026 | 2,199,381 | +442,447 | $5.4M | -42.9% | 0.07% | EC |
| 128 | ORIC Pharmaceuticals, Inc. | 68622P109 | Mar 2026 | 424,422 | +94,873 | $5.4M | +36.0% | 0.07% | EC |
| 129 | Castle Biosciences, Inc. | 14843C105 | Mar 2026 | 215,689 | +49,568 | $5.3M | +40.0% | 0.07% | EC |
| 130 | Annexon, Inc. | 03589W102 | Mar 2026 | 952,884 | +391,819 | $5.3M | +208.5% | 0.06% | EC |
| 131 | Kura Oncology, Inc. | 50127T109 | Mar 2026 | 628,449 | +132,190 | $5.1M | +16.3% | 0.06% | EC |
| 132 | Inhibrx Biosciences, Inc. | 45720N103 | Mar 2026 | 75,835 | +17,678 | $5.1M | +160.3% | 0.06% | EC |
| 133 | Arbutus Biopharma Corp. | 03879J100 | Mar 2026 | 1,119,437 | +242,128 | $5.0M | +26.5% | 0.06% | EC |
| 134 | ArriVent Biopharma, Inc. | 04272N102 | Mar 2026 | 201,242 | +25,364 | $4.6M | +43.1% | 0.06% | EC |
| 135 | Cullinan Therapeutics, Inc. | 230031106 | Mar 2026 | 323,429 | +103,790 | $4.6M | +252.9% | 0.06% | EC |
| 136 | Replimune Group, Inc. | 76029N106 | Mar 2026 | 570,930 | +193,631 | $4.4M | +176.3% | 0.05% | EC |
| 137 | Precigen, Inc. | 74017N105 | Mar 2026 | 1,104,713 | +234,422 | $4.3M | +49.3% | 0.05% | EC |
| 138 | Arvinas, Inc. | 04335A105 | Mar 2026 | 403,100 | +24,178 | $4.3M | +32.4% | 0.05% | EC |
| 139 | Savara, Inc. | 805111101 | Mar 2026 | 775,563 | +297,421 | $4.2M | +148.1% | 0.05% | EC |
| 140 | Ironwood Pharmaceuticals, Inc. | 46333X108 | Mar 2026 | 1,173,471 | +251,556 | $4.1M | +241.0% | 0.05% | EC |
| 141 | Phathom Pharmaceuticals, Inc. | 71722W107 | Mar 2026 | 356,945 | +132,820 | $4.0M | +50.3% | 0.05% | EC |
| 142 | Zevra Therapeutics, Inc. | 488445206 | Mar 2026 | 413,742 | +86,577 | $3.9M | +23.9% | 0.05% | EC |
| 143 | Cytek Biosciences, Inc. | 23285D109 | Mar 2026 | 868,726 | +187,560 | $3.8M | +60.6% | 0.05% | EC |
| 144 | ARS Pharmaceuticals, Inc. | 82835W108 | Mar 2026 | 463,404 | +124,031 | $3.7M | +9.1% | 0.05% | EC |
| 145 | Sana Biotechnology, Inc. | 799566104 | Mar 2026 | 1,235,916 | +383,395 | $3.6M | +17.6% | 0.04% | EC |
| 146 | Rigel Pharmaceuticals, Inc. | 766559702 | Mar 2026 | 131,031 | +28,123 | $3.5M | +21.5% | 0.04% | EC |
| 147 | Compass Pathways plc | 20451W101 | Mar 2026 | 612,150 | +235,040 | $3.4M | +56.7% | 0.04% | EC |
| 148 | OPKO Health, Inc. | 68375N103 | Mar 2026 | 2,882,600 | +770,215 | $3.3M | +0.4% | 0.04% | EC |
| 149 | Solid Biosciences, Inc. | 83422E204 | Mar 2026 | 446,552 | +100,535 | $3.2M | +50.6% | 0.04% | EC |
| 150 | 4D Molecular Therapeutics, Inc. | 35104E100 | Mar 2026 | 338,744 | +84,709 | $3.2M | +42.9% | 0.04% | EC |
| 151 | Emergent BioSolutions, Inc. | 29089Q105 | Mar 2026 | 376,503 | +75,513 | $3.1M | +17.7% | 0.04% | EC |
| 152 | Myriad Genetics, Inc. | 62855J104 | Mar 2026 | 662,895 | +141,963 | $3.0M | -20.8% | 0.04% | EC |
| 153 | Absci Corp. | 00091E109 | Mar 2026 | 975,088 | +204,457 | $2.9M | +24.9% | 0.04% | EC |
| 154 | Perspective Therapeutics, Inc. | 46489V302 | Mar 2026 | 693,460 | +335,293 | $2.9M | +135.4% | 0.04% | EC |
| 155 | Altimmune, Inc. | 02155H200 | Mar 2026 | 926,610 | +423,158 | $2.9M | +50.4% | 0.04% | EC |
| 156 | Vanda Pharmaceuticals, Inc. | 921659108 | Mar 2026 | 405,038 | +80,628 | $2.8M | +72.9% | 0.03% | EC |
| 157 | Allogene Therapeutics, Inc. | 019770106 | Mar 2026 | 1,145,572 | +231,657 | $2.8M | +146.7% | 0.03% | EC |
| 158 | REGENXBIO, Inc. | 75901B107 | Mar 2026 | 331,423 | +61,506 | $2.8M | +6.6% | 0.03% | EC |
| 159 | Rocket Pharmaceuticals, Inc. | 77313F106 | Mar 2026 | 752,567 | +169,564 | $2.7M | +41.8% | 0.03% | EC |
| 160 | Pacific Biosciences of California, Inc. | 69404D108 | Mar 2026 | 2,021,533 | +462,422 | $2.7M | +33.7% | 0.03% | EC |
| 161 | Lexeo Therapeutics, Inc. | 52886X107 | Mar 2026 | 457,447 | +186,991 | $2.6M | +46.2% | 0.03% | EC |
| 162 | Enanta Pharmaceuticals, Inc. | 29251M106 | Mar 2026 | 205,184 | +89,528 | $2.6M | +87.2% | 0.03% | EC |
| 163 | Standard BioTools, Inc. | 34385P108 | Mar 2026 | 2,747,556 | +592,420 | $2.5M | -9.8% | 0.03% | EC |
| 164 | Design Therapeutics, Inc. | 25056L103 | Mar 2026 | 235,859 | +52,200 | $2.5M | +81.5% | 0.03% | EC |
| 165 | Personalis, Inc. | 71535D106 | Mar 2026 | 393,153 | +80,963 | $2.5M | +23.0% | 0.03% | EC |
| 166 | Atea Pharmaceuticals, Inc. | 04683R106 | Mar 2026 | 460,056 | +80,920 | $2.5M | +125.1% | 0.03% | EC |
| 167 | Prime Medicine, Inc. | 74168J101 | Mar 2026 | 704,092 | +147,403 | $2.5M | -20.6% | 0.03% | EC |
| 168 | Keros Therapeutics, Inc. | 492327101 | Mar 2026 | 214,789 | +14,886 | $2.4M | -25.0% | 0.03% | EC |
| 169 | Fulgent Genetics, Inc. | 359664109 | Mar 2026 | 148,748 | +32,402 | $2.4M | -10.1% | 0.03% | EC |
| 170 | Tectonic Therapeutic, Inc. | 878972108 | Mar 2026 | 75,889 | +14,369 | $2.3M | +143.0% | 0.03% | EC |
| 171 | Aura Biosciences, Inc. | 05153U107 | Mar 2026 | 338,128 | +93,190 | $2.3M | +49.4% | 0.03% | EC |
| 172 | Kyverna Therapeutics, Inc. | 501976104 | Mar 2026 | 251,263 | +122,491 | $2.2M | +180.7% | 0.03% | EC |
| 173 | Maravai LifeSciences Holdings, Inc. | 56600D107 | Mar 2026 | 759,052 | +149,573 | $2.1M | +22.8% | 0.03% | EC |
| 174 | Anavex Life Sciences Corp. | 032797300 | Mar 2026 | 668,447 | +178,938 | $2.1M | -52.9% | 0.03% | EC |
| 175 | Entrada Therapeutics, Inc. | 29384C108 | Mar 2026 | 158,267 | +21,061 | $2.0M | +151.0% | 0.02% | EC |
| 176 | Ginkgo Bioworks Holdings, Inc. | 37611X209 | Mar 2026 | 317,323 | +78,444 | $1.9M | -44.1% | 0.02% | EC |
| 177 | Neurogene, Inc. | 64135M105 | Mar 2026 | 94,694 | +22,201 | $1.9M | +52.0% | 0.02% | EC |
| 178 | LENZ Therapeutics, Inc. | 52635N103 | Mar 2026 | 206,971 | +65,220 | $1.9M | -71.3% | 0.02% | EC |
| 179 | Autolus Therapeutics plc | 05280R100 | Mar 2026 | 1,321,681 | +321,286 | $1.8M | +11.9% | 0.02% | EC |
| 180 | Editas Medicine, Inc. | 28106W103 | Mar 2026 | 731,163 | +219,510 | $1.8M | +1.7% | 0.02% | EC |
| 181 | C4 Therapeutics, Inc. | 12529R107 | Mar 2026 | 608,839 | +255,062 | $1.6M | +103.9% | 0.02% | EC |
| 182 | Larimar Therapeutics, Inc. | 517125100 | Mar 2026 | 350,415 | +63,752 | $1.6M | +70.3% | 0.02% | EC |
| 183 | Arcturus Therapeutics Holdings, Inc. | 03969T109 | Mar 2026 | 186,967 | +40,371 | $1.4M | -46.6% | 0.02% | EC |
| 184 | Voyager Therapeutics, Inc. | 92915B106 | Mar 2026 | 329,043 | +64,987 | $1.3M | +3.0% | 0.02% | EC |
| 185 | Bicycle Therapeutics plc | 088786108 | Mar 2026 | 244,101 | +60,583 | $1.1M | -20.3% | 0.01% | EC |
| 186 | Codexis, Inc. | 192005106 | Mar 2026 | 683,417 | +188,506 | $1.1M | -7.8% | 0.01% | EC |
| 187 | Lyell Immunopharma, Inc. | 55083R203 | Mar 2026 | 54,413 | +3,623 | $1.1M | +32.3% | 0.01% | EC |
| 188 | Foghorn Therapeutics, Inc. | 344174107 | Mar 2026 | 223,190 | +46,893 | $1.1M | +23.8% | 0.01% | EC |
| 189 | Quanterix Corp. | 74766Q101 | Mar 2026 | 284,827 | +53,360 | $1.0M | -20.2% | 0.01% | EC |
| 190 | Silence Therapeutics plc | 82686Q101 | Mar 2026 | 173,313 | +140,776 | $913K | +440.9% | 0.01% | EC |
| 191 | Neumora Therapeutics, Inc. | 640979100 | Mar 2026 | 421,430 | +13,311 | $822K | +10.6% | 0.01% | EC |
| 192 | PepGen, Inc. | 713317105 | Mar 2026 | 451,333 | +274,004 | $799K | -2.5% | 0.01% | EC |
| 193 | Humacyte, Inc. | 44486Q103 | Mar 2026 | 1,222,120 | +453,285 | $741K | -44.6% | 0.01% | EC |
| 194 | Pyxis Oncology, Inc. | 747324101 | Mar 2026 | 345,130 | +89,826 | $504K | -11.1% | 0.01% | EC |
| 195 | Immutep Ltd. | 45257L108 | Mar 2026 | 809,244 | +215,082 | $284K | -72.7% | 0.00% | EC |
| 196 | Alpha Teknova, Inc. | 02080L102 | Mar 2026 | 79,636 | +11,537 | $230K | -45.4% | 0.00% | EC |